Corbus Pharmaceuticals Advances CRB-913 for Obesity Treatment: Phase 1 Trial Underway Published: march 28,2025 A New Hope for Obesity Treatment: Corbus’s CRB-913 Enters Phase 1 trials Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a company focused on both oncology and obesity solutions, has announced a meaningful step forward in its obesity program. The first participant has … Read more
You can read the full story here: Corbus’ CRB-913: Phase 1 Obesity Trial Begins .
